Chart 2.

Indication of Colegio et al. for revising the immunosuppression regimen (26)

Indications for immunosuppression revision
5-10 well differentiated SCCs per year
1 SCC with 2 high-risk AJCC features*
Recurrent SCC
SCC with in-transit metastasis
Metastatic SCC

^*Breslow tumor thickness greater than 2mm, Clark level > IV (into the reticular dermis), perineural invasion, anatomic site (ear, nonglabrous lip) and degree of histologic differentiation (poorly differentiated or undifferentiated).